Our Latest News

Stay tuned with Golden Helix Foundation

On behalf of the organizing committee, we are delighted to welcome you at the 7th U-PGx Personalized Medicine Day that will be organized in Ljubljana, Slovenia on March 24th, 2021. 

The meeting will be co-organized by the Golden Helix Foundation and the University of Ljubljana, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353). This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.

In light of the coronavirus pandemic, the U-PGx Executive Board has made the decision to hold the 7th U-PGx Personalized Medicine Day as a VIRTUAL meeting and the meeting will start at 9 am CET.

We look forward to a successful meeting.

 

 

Organizing entities:

 

 

Funded by:


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668353.

 

 

London, 2 January 2021

Job Description

The European Commission has been funded a R&D project entitled “Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen” under the Call H2020-PHC-2015-two-stage (Prj No. 668353-2).

Pharmacogenomics (PGx) is the study of genetic variability affecting an individual’s response to a drug. Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in PGx and several commercially available PGx tests, its application in routine patient care remains very limited.

The U-PGx consortium will address major challenges and obstacles for implementation of PGx testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important PGx markers is cost-effective and results in a better outcome for patients. With the pre-emptive PGx testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive PGx-testing will be conducted at a large scale in seven existing European health care environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).

The Golden Helix Foundation is leader of the work package WP5: Health Technology Assessment (HTA) and cost-effectiveness analysis and responsible for the Proposition and implementation of a new EU model and methodological concept of cost-effectiveness analysis, taking into account the restriction of budget.

The selected candidates will be involved in the implementation of the Task 5.3 based on the collected data from the University of Patras. More specifically, he/she will be responsible for: 

1.    Propose an alternative methodological approach for decision making which takes into account the budget constraint and relaxing the constant-return-on-scale assumption of λ. In other words, the new model will combine the cost-effectiveness analysis, budget impact analysis and social preferences while relaxing the assumption that willingness to pay (λ) is indifferent of the actual difference in effectiveness between interventions. This rational would provide a practical guide by which policy makers could ensure the sustainability of funding given the restriction of budget;

2.    Based on the classical decision making approach of cost effectiveness analysis, ICER is compared with a fixed amount which a policymaker is willing to pay (λ) for an additional QALY. In this methodology context, if ICER is below λ, the new intervention meets the basic criterion for reimbursement by the payers, assuming that the policy makers are willing to pay this amount, regardless of the amount of QALYs “purchased”, ignoring in that way the budget constraint;

3.    Certain limitations must be considered in this approach, since there is no clear linkage between λ and the budget affordability of health services, while it assumes, silently, an instant adjustment of budget to absorb the cost of innovation, which may lead to the adoption of costly decisions which can consequently increase expenditures for healthcare systems. Even if the budget does not face hard constraints, it is reasonable to assume that there is an upper budget bound, especially nowadays in the presence of global economic crisis.

4.    The envisaged model represents the link between the willingness to pay threshold towards the budget limit, which can be particularly helpful in developing and resource-limited countries, where there are often significant budget limitations. As such, this model would provide a new conceptual methodology for the betterment of our understanding in decision making process and would be particularly useful to perform economic evaluation studies of novel genomic medicine interventions in different EU member states and healthcare systems to assess cost consequences of the implementation of pharmacogenomic testing, taking into account healthcare budget differences, so that resource allocation in these countries could be optimized;

5.    Outcomes will also provide essential insights for guiding European health insurance organizations and national stakeholders in strategies for reimbursement of PGx testing.

The Golden Helix Foundation is organising an open competition, based on qualifications, to recruit new researchers to undertake the above described task. This notice covers three positions. A candidate may only apply to one of them.

COMPETITION ANNOUNCEMENT FORM

ORGANISATION/COMPANY: Golden Helix Foundation

POSITION 1: Researcher on Health Technology Assessment (HTA) and cost-effectiveness analysis of data collected by the University of Patras, Greece

SCIENTIFIC FIELD: Bioinformatics

DURATION: Jan. 2021 to June 2021

START DATE (earliest): January 11, 2021

PROJECT DURATION: Up to June 30, 2021 with possibility of extension according to the needs of the project

BUDGET (aprox.): 4,827.35 euro /month 

ANNOUNCEMENT DATE: 02.01.2021

ENTRY DEADLINE: 09.01.2021

LINK TO WEBSITE: https://www.goldenhelix.org/

KEY WORDS: bioinformatics, pharmacogenomics, individualized medicine, generic economic model

DESCRIPTION: (subject matter, expectations, opinions):

I. Candidates should have:

1. university education - completed 1st and 2nd degree studies in pharmacy 2. average of all grades at five-year university at least 6.5 of 10 3. Ph.D holder 4. substantiated research experience on bioinformatics and pharmacogenomics in the country or abroad 5. Excellent English and Greek language competence 6. predispositions for scientific research and didactic work confirmed by scientific supervisor 7. substantiated publications on international journals or conferences.

 

COMPETITION ANNOUNCEMENT FORM

ORGANISATION/COMPANY: Golden Helix Foundation

POSITION 2: Senior Researcher on Health Technology Assessment (HTA) and cost-effectiveness analysis of data collected by the University of Patras, Greece

SCIENTIFIC FIELD: Psychiatric genomics

DURATION: Jan. 2021 to June 2021

START DATE (earliest): January 11, 2021

PROJECT DURATION: Up to June 30, 2021 with possibility of extension according to the needs of the project

BUDGET (aprox.): 5,016.55 euro /month 

ANNOUNCEMENT DATE: 02.01.2021

ENTRY DEADLINE: 09.01.2021

LINK TO WEBSITE: https://www.goldenhelix.org/

KEY WORDS: genomics, psychiatric, patient recruitment, pharmacogenomics, individualized medicine, generic economic model

DESCRIPTION: (subject matter, expectations, opinions):

I. Candidates should have:

1. university education - completed 1st and 2nd degree studies in chemistry, biochemistry and biotechnology 2. average of all grades at four-year university at least 6.5 of 10 3. Ph.D holder 4. substantiated research experience in psychiatric genomics and pharmacogenomics in the country or abroad 5. Excellent English and Greek language competence 6. predispositions for scientific research and didactic work confirmed by scientific supervisor 7. substantiated work experience at least four years on large scale R&D projects 8. substantiated publications on international journals and conferences.

 

COMPETITION ANNOUNCEMENT FORM

ORGANISATION/COMPANY: Golden Helix Foundation

POSITION 3: Researcher on Health Technology Assessment (HTA) and cost-effectiveness analysis using a newly generated generic economic model

SCIENTIFIC FIELD: Informatics

DURATION: Jan. 2021 to June 2021

START DATE (earliest): January 11, 2021

PROJECT DURATION: Up to June 30, 2021 with possibility of extension according to the needs of the project

BUDGET (aprox.): 4,094.31 euro /month

ANNOUNCEMENT DATE: 02.01.2021

ENTRY DEADLINE: 09.01.2021

LINK TO WEBSITE: https://www.goldenhelix.org/

KEY WORDS: genomics, psychiatric, patient recruitment, pharmacogenomics, individualized medicine, generic economic model

DESCRIPTION: (subject matter, expectations, opinions):

I. Candidates should have:

1. university education - completed 1st and 2nd degree studies in computing and information technology 2. average of all grades at four-year university at least 6.5 of 10 3. substantiated research experience in information technology and genetic databases in the country or abroad 4. Excellent English and Greek language competence 5. substantiated publications on international journals and conferences.

 

COMPETITION ANNOUNCEMENT FORM

ORGANISATION/COMPANY: Golden Helix Foundation 

POSITION 4: Researcher on Health Technology Assessment (HTA) and cost-effectiveness analysis of data collected by the University of Patras, Greece and on PGx awareness to stakeholders 

SCIENTIFIC FIELD: Medical Molecular Genetics Analysis 

DURATION: Jan. 2021 to June 2021

START DATE (earliest): January 11, 2021

PROJECT DURATION: Up to June 30, 2021 with possibility of extension according to the needs of the project

BUDGET (aprox.): 5,446.54 euro /month

ANNOUNCEMENT DATE: 02.01.2021 

ENTRY DEADLINE: 09.01.2021 

LINK TO WEBSITE: https://www.goldenhelix.org/

KEY WORDS: pharmacogenomics, individualized medicine, dissemination 

DESCRIPTION: (subject matter, expectations, opinions):

I. Candidates should have:

1. university education - completed 1st degree studies in biology 2. average of all grades at four-year university at least 6.5 of 10 3. Ph.D holder 4. substantiated research experience on molecular genetics analysis, on pharmacogenomics and on dissemination of research outputs in the country or abroad 5. Excellent English and Greek language competence 6. predispositions for scientific research and didactic work confirmed by scientific supervisor 7. substantiated publications on international journals or conferences. 

Eligibility criteria

II. The application should include:

1. Application form to Managing Director, CV 2. Copy of the university 1st and 2nd degree certifications 3. Copy of Ph.D or M.Sc diplomas 4. List of scientific achievements and publications with number of points 5. Copy of research and work experience certifications 6. Statement of consent to the processing of personal data contained in the offer.

 

Documents confirming the qualifications and abilities should be submitted at the Golden Helix foundation, 16, Northumberland avenue, Craven House, London WC2N 5AP, United Kingdom, till 09.01.2021.

Web site for additional job details

https://www.goldenhelix.org/

 

 

The result of the competition will be announced on the Website of the Foundation.

 

This landmark symposium, presented by The Golden Helix Foundation and the Pharmacogenomics Access & Reimbursement Coalition (PARC), was one-day interactive event made up of plenary keynotes from thought leaders across healthcare, focused on value-based strategies to improve patient access to personalized medicine. 

Stakeholders including patients, providers, industry, government agencies, payer organizations, health systems and health policy organizations will convene to define opportunities to improve patient access to personalized medicine through best practices, successful reimbursement models, high quality economic evaluations and strategic alignment.

 Topics was discussed at PARS 2020:

• Comparative Effectiveness Research for pharmacogenomics

• State-of-the-art value assessment frameworks for pharmacogenetics testing

• Pulling back the curtain on real-world evidence and pharmacogenomics

• New frontiers in cost containment

• Economic evaluations: ensuring quality trials and addressing challenges

• New methods and measures for improved economic evaluation and efficiency measures in pharmacogenomics to gain advances in increasing value and promote health-seeking behavior

• Identifying the most promising payer engagement strategies

• Strategies for producers and payers to collaborate throughout the product life cycle

 

View the embedded image gallery online at:
https://www.goldenhelix.org/news/latest-news#sigProId62ef12aba4

 

 

  

The 3rd U-PGx Personalized Medicine Public Day was successfully co-organized in Patras, Greece by the Golden Helix Foundation together with the University of Patras, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualized Therapy (Patras, Greece). The meeting was attended by more than 450 participants and coordinated by Ms Clelia Charissis, who moderated the afternoon and evening sessions.

The theme of the meeting was “Pharmacogenomics and Personalized Medicine”, was organized in Agora Argyri congress venue on September 26th, 2019 and was part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353).

In particular, there were three main events, as part of the 3rd Personalized Medicine Public Day:

1. 09:00 – 14:00: Practical demonstration of the 2MoBiL Portable Molecular Biology Laboratory and its role in Personalized Medicine education for school students,

2. 17:00 – 20:00: Main event: Presentations and roundtable discussion of Personalized Medicine notions

3. 20:00 – 22:00: Bioscience night: Interactive discussions on Personalized Medicine topics.

This event was meant for the general public, patient organisations, regulators, insurers and policy makers. Registration was FREE-OF-CHARGE.

Please visit the following links for more photos, videos and details for this event (content in Greek)

• http://bit.ly/2m581c2

• https://youtu.be/NYhEEhgJQrM

• https://youtu.be/WaEQL98Wnos

• https://www.youtube.com/watch?v=R-iRbwjlEUg

• https://www.youtube.com/watch?v=WgvMmajlfZM

• https://www.youtube.com/watch?v=WgvMmajlfZM

• https://www.youtube.com/watch?v=PQbRMGwKioU

• https://www.youtube.com/watch?v=BSD7gpKvZFs

• https://www.youtube.com/watch?v=NYhEEhgJQrM

• https://flashstars.gr/me-megali-epitychia-pragmatopoiithike-i-3i-imerida-exatomikeymenis-iatrikis/

• https://www.patratv.gr/index.php/features/2016-02-15-11-01-13/87714-ημερίδα-εξατομικευμένης-ιατρικής

• https://www.envivlio.com/club341

• https://www.zougla.gr/ygeia/article/simantikes-parousiasis-stin-3i-imerida-eksatomikevmenis-iatrikis

• https://www.achaianews.gr/index.php/όλα-τα-νέα-h/κοινωνια/87714-ημερίδα-εξατομικευμένης-ιατρικής

 

 

We are seeking a marketing or professional congress organizing company or expert to provide services for the organization of the 2nd U-PGx Personalized Medicine Public Daythat will be held in Rome, Italy, on January 21st, 2019 at the Fleming Auditorium of the Università degli Studi di Roma “Tor Vergata”. This meeting will be co-organized by the Università degli Studi di Roma “Tor Vergata” and the Golden Helix Foundation, partner of the Ubiquitous Pharmacogenomics (U-PGx) project (http://www.upgx.eu), funded by the European Commission (H2020-668353).

This international event is open for the general public, the patient organisations,  the regulators,the insurers and for everybody interested in pharmacogenomics. For more information please visit http://www.goldenhelix.org/conferences/pharmacogenomics-days/upcomingconferences (/conferences/pharmacogenomics-days/upcoming-conferences).

Selected company or person will be asked to provide the following services:

- Arranging accommodation for guest speakers (6-8 rooms in up to 4* hotels),

- Arranging for the delivery of catering by a local provider (including 1 coffee break and a light lunch for all the participants (110-15 people) during the event),

- Website development and updating the web-based online registration system,

- Design of promotional material for the event (1st announcement (1000 copies), advertising banner)

- Advertisement of the event in various websites and public press with high attendance and accesible by wide audincies, mailing lists

- create a short list of proposed conferences where the event could be sponsored

- payment of the sponsorship in selected conferences,

- Social Media Consulting and Management,

- Content strategy development for social media channels and write/publish 3 posts each week or 12 per month,

- Design and production of printed material (including brochures, roll-up banners, participants’ name tags (110-150, depending on the number of registered participants),

- Provide notepads and pens for meeting participants (110-150, depending on the number of registered participants),

- Design and printing of the scientific program in a pre-determined format, (110-150 copies, depending on the number of registered participants),

- Printing of folders for participants (110-150, depending on the number of registered participants),

- Provision of communication and advertisement services of the event, including official announcement of the meeting, event campaigns, invitations - sent by e-mail to targeted recipients, advertisement plan (magazines, newspapers, radio and news websites) promoting the event to the local, regional and international network.

To express your interest, please contact: secretariat [AT] goldenhelix [DOT] org with Subject “CEI – Rome 2019”, including:

1. your offer,

2. a detailed description of the proposed activities,

3. a profile and track record of your company

It would be preferable canditates with experience of provision of marketing services on projects funded by Horizon framework..

 

Deadline: November 30th, 2018

We are seeking a marketing or professional congress organizing company or expert to provide services for the organization of the 6th U-PGx Personalized Medicine Day, that will be held in Stuttgart, Germany, on February 25th, 2019 at the same place where the 4th German Pharm-Tox Summit wil be organized. This meeting will be organized by the Golden Helix Foundation,  partner of the Ubiquitous Pharmacogenomics (U-PGx) (http://www.upgx.eu) project, funded by the European Commission (H2020-668353).

This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics. For more information please visit http://www.goldenhelix.org/conferences/pharmacogenomics-days/upcomingconferences (Conferences / Pharmacogenomics days / Upcoming conferences).

Selected company or will be asked to provide the following services:

- Arranging accommodation for guest speakers (3-4 rooms in up to 4* hotels),

- Website development and updating the web-based online registration system,

- Design of promotional material for the event (1st announcement (500 copies), advertising banner)

- Advertisement of the event in websites, mailing lists, other conferences,

- Social Media Consulting and Management,

- Content strategy development for social media channels and write/publish 2 posts each week or 8 per month,

- Design and production of printed material (including brochures, roll-up banners, participants’ name tags (80-110, depending on the number of registered participants),

- Provide notepads and pens for meeting participants (80-110, depending on the number of registered participants),

- Design and printing of the scientific program in a pre-determined format, (80-110 copies, depending on the number of registered participants),

- Printing of folders for participants (80-110, depending on the number of registered participants),

- Provision of communication and advertisement services of the event, including official announcement of the meeting, event campaigns, invitations - sent by e-mail to targeted recipients, advertisement plan (magazines, newspapers, and news websites) promoting the event to the local, regional and international network.

To express your interest, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

(mailto:This email address is being protected from spambots. You need JavaScript enabled to view it.) with Subject “CEI – Germany 2019”, including:

1. Your offer,

2. A detailed description of the proposed activities,

3. A profile and track record of your company

DEADLINE for applications: November 30th, 2018